CAM
JANX icon

Congress Asset Management’s Janux Therapeutics JANX Stock Holding History

Congress Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
67,610
+743
+1% +$10.8K 0.01% 304
2026
Q1 		$929K Buy
66,867
+9,525
+17% +$131K 0.01% 343
2025
Q4 		$791K Buy
57,342
+1,569
+3% +$36.9K 0.01% 324
2025
Q3 		$1.36M Buy
+55,773
New +$1.36M 0.01% 304

Other funds holding JANX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Congress Asset Management's JANX Position: Q2 2026 in Review

Congress Asset Management increased its Janux Therapeutics (JANX) stake by 1.1% in Q2 2026, buying an estimated $10.8K and bringing the position to 67,610 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #304.

Congress Asset Management first reported a position in JANX in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.36M in Q3 2025. 24 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Congress Asset Management held 67,610 shares of Janux Therapeutics worth $1.04M as of Q2 2026.
  • Congress Asset Management bought 743 Janux Therapeutics shares in Q2 2026, an estimated $10.8K.
  • Janux Therapeutics made up 0.01% of Congress Asset Management's portfolio in Q2 2026, its #304 holding.
  • Congress Asset Management first reported a position in Janux Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Congress Asset Management's Janux Therapeutics position peaked at $1.36M in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.